Fibrinogen inhibits sonic hedgehog signaling and impairs neonatal cerebellar development after blood-brain barrier disruption.
coagulation
neurovascular
preterm Infant
stem/progenitor cell
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
ppublish
Résumé
Cerebellar injury in preterm infants with central nervous system (CNS) hemorrhage results in lasting neurological deficits and an increased risk of autism. The impact of blood-induced pathways on cerebellar development remains largely unknown, so no specific treatments have been developed to counteract the harmful effects of blood after neurovascular damage in preterm infants. Here, we show that fibrinogen, a blood-clotting protein, plays a central role in impairing neonatal cerebellar development. Longitudinal MRI of preterm infants revealed that cerebellar bleeds were the most critical factor associated with poor cerebellar growth. Using inflammatory and hemorrhagic mouse models of neonatal cerebellar injury, we found that fibrinogen increased innate immune activation and impeded neurogenesis in the developing cerebellum. Fibrinogen inhibited sonic hedgehog (SHH) signaling, the main mitogenic pathway in cerebellar granule neuron progenitors (CGNPs), and was sufficient to disrupt cerebellar growth. Genetic fibrinogen depletion attenuated neuroinflammation, promoted CGNP proliferation, and preserved normal cerebellar development after neurovascular damage. Our findings suggest that fibrinogen alters the balance of SHH signaling in the neurovascular niche and may serve as a therapeutic target to mitigate developmental brain injury after CNS hemorrhage.
Identifiants
pubmed: 39042684
doi: 10.1073/pnas.2323050121
doi:
Substances chimiques
Hedgehog Proteins
0
Fibrinogen
9001-32-5
Shh protein, mouse
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2323050121Subventions
Organisme : HHS | National Institutes of Health (NIH)
ID : K02NS110973
Organisme : HHS | National Institutes of Health (NIH)
ID : R01NS126498
Organisme : HHS | National Institutes of Health (NIH)
ID : R35NS097976
Déclaration de conflit d'intérêts
Competing interests statement:K.A. is the scientific founder, advisor, and shareholder of Therini Bio, Inc. and has served as a consultant for F. Hoffmann-La Roche. Her interests are managed by Gladstone Institutes according to its conflict of interest policy. The other authors declare that they have no competing interests.